Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Omeros Corp (OMER)

Omeros Corp (OMER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Omeros: Q3 Earnings Snapshot

Omeros: Q3 Earnings Snapshot

OMER : 10.91 (+41.14%)
Omeros: Q2 Earnings Snapshot

Omeros: Q2 Earnings Snapshot

OMER : 10.91 (+41.14%)
Omeros: Q1 Earnings Snapshot

Omeros: Q1 Earnings Snapshot

OMER : 10.91 (+41.14%)
Omeros: Q4 Earnings Snapshot

Omeros: Q4 Earnings Snapshot

OMER : 10.91 (+41.14%)
Omeros: Q3 Earnings Snapshot

Omeros: Q3 Earnings Snapshot

OMER : 10.91 (+41.14%)
Omeros: Q2 Earnings Snapshot

Omeros: Q2 Earnings Snapshot

OMER : 10.91 (+41.14%)
Why Shares of Omeros Dropped on Monday

The clinical-stage biopharmaceutical released trials data through a presentation.

OMER : 10.91 (+41.14%)
Omeros: Q1 Earnings Snapshot

Omeros: Q1 Earnings Snapshot

OMER : 10.91 (+41.14%)
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes....

OMER : 10.91 (+41.14%)
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve...

OMER : 10.91 (+41.14%)

Barchart Exclusives

How to Invest for Kids: Understanding the Basics
A good way to show kids the value of compounding money is to ask if they’d rather have a $100 bill today or a penny that doubles every day for 30 days. They will be surprised to hear that in 30 days, that penny would be worth about $5.4 million dollars! Here's a guide to the types of accounts you can open for your children or grandchildren. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar